Evaluating the Efficacy and Risks of Early Lecanemab Treatment in APOE4 Humanized Alzheimer's Disease Mouse Models
Early mAb158 treatment reduces key Alzheimer's disease pathology but fails to prevent attention deficits in hApp<sup>NL-F</sup>-hMAPT-APOE4 mice and may increase microbleeds in this vulnerable group. By combining new generation mouse models of genetic AD risk with translational cognitive and imaging biomarkers, we propose a preclinical platform to better predict the safety and efficacy of monoclonal antibody treatments.
Authors
- Ebrima Gibbs (ORCID: https://orcid.org/0000-0002-6383-9239)
- Arash Salahinejad (ORCID: https://orcid.org/0000-0001-7644-1273)
- Johanne Kaplan
- Vânia F. Prado (ORCID: https://orcid.org/0000-0003-4994-6393)
- Czarina Evangelista (ORCID: https://orcid.org/0000-0002-7745-5252)
- Scott Napper (ORCID: https://orcid.org/0000-0003-1948-4538)
- Taylor W. Schmitz
- Marco AM Prado
- Kellly Summers
- Kate M. Onuska
- Mohammad H Alipour
- Neil R Cashman
- Lisa M Saksida
- Timothy J Bussey
- Amr Eed
- Ravi S. Menon
- Luke Smolders
Institutions
- Western University (CA)
- Lawson Health Research Institute (CA)
- University of British Columbia (CA)
- University of Saskatchewan (CA)
- Robarts Clinical Trials (CA)
- Amorfix (Canada) (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70855_102371
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00